Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Overview publication

TitleEfficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
DateDecember 1st, 2020
Issue nameThe Lancet Diabetes & Endocrinology
Issue numberv8.12 p960-970
DOI10.1016/s2213-8587(20)30364-8
AuthorsClément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P, Pigeon-Kherchiche P, Flaus-Furmaniuk A, Bald M, Denzer C, von Schnurbein J, Abawi O, Blume-Peytavi U, Krabusch P, Mai K, Schnabel D, Wiegand S, Flück CE, Schulz E, Voss E, Bratina N, Weiss K, Martos-Moreno GÃ, Danset A, Gougis P, Dubern B, Clément K, van den Akker EL, Argente J, Bahm AL, Chung WK, Connors HS, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon GA, Poitou C, Puder L, Swain JM, Stewart MW, Yuan G, Wabitsch M & Kühnen P
MTGsMTG6
Read Read publication